A poster titled, “Real World Evidence Guides Academic Health System to Inform Hospital Pharmacy Formulary & Impart Cost-Effective Care” was presented at the American Society of Health-System Pharmacists (ASHP) by authors Neera Ahuja, MD, Janjri Desai, PharmD, MBA, Valerie Garrett, MD, MPH, and Saurabh Gombar, MD, PhD. Dr. Ahuja and Dr. Desai are affiliated with Stanford University School of Medicine. Dr. Garrett and Dr. Gombar, Chief Medical Officer and Co-founder, are affiliated with Atropos Health.
Short Summary:
Stanford Health Care experienced marked increases in high-cost perineural liposomal bupivacaine use from 2015 to 2021. This poster examined the use of liposomal bupivacaine and found that Orthopedics accounted for 60% of it’s use. Using Sanford EHR data and leveraging the Green Button™ consult with statistical analysis by Atropos Health, the health system learned valuable insights on health outcomes when comparing high and low-cost drugs. In fact:
- Stanford Health Care real-world evidence findings of non-superior clinical outcomes with high-cost liposomal bupivacaine were found to be consistent with recent meta-analysis
- And, the health system could realize an annualized cost savings in Year 1 from retiring the drug estimated at $193,883
To learn how Atropos Health can accelerate and supplement your research with Real-World Evidence (RWE), email us: sales@atroposhealth.com